Gallium-68 PSMA

Drug Profile

Gallium-68 PSMA

Alternative Names: (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; (68Ga)PSMA-HBED-CC; 68Ga-DKFZ-PSMA-11; 68Ga-HBED-CC-PSMA; 68Ga-PSMA; 68Ga-PSMA HBED-CC; 68Ga-PSMA HBED-PET/CT; 68Ga-PSMA ligand Glu-urea-Lys(Ahx)-HBED-CC; 68Ga-PSMA-11; 68Ga-PSMA-ligand; Ga-68 labeled DKFZ-PSMA-11; Ga-68 labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; Ga-68 labeled Glu-urea-Lys(Ahx)-HBED-CC; Ga-68 labeled PSMA-11 PET; Ga-68-PSMA-11; Gallium-68 labeled PSMA-11; ProstaMedix; PSMA-HBED-CC GA-68

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator RadioMedix
  • Developer Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori; Medical University of Vienna; Princess Alexandra Hospital; Sir Charles Gairdner Hospital; University of California at San Francisco
  • Class Imaging agents; Oligopeptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Renal cell carcinoma

Most Recent Events

  • 04 Jan 2017 Prostate Cancer Foundation of Australia and Peter MacCallum Cancer Centre plan the ProPSMA clinical trial for Prostate cancer (Diagnosis) in Australia (ACTRN12617000005358p)
  • 21 Dec 2016 Sir Mortimer B. Davis - Jewish General Hospital and Isologic Innovative Radiopharmaceuticals plan a phase III trial for Prostate cancer (Diagnosis) in Canada (IV) (NCT03001869)
  • 01 Sep 2016 National Cancer Institute and Jonsson Comprehensive Cancer Center initiate a clinical trial for Prostate cancer (Diagnosis) in USA (IV) (NCT02940262)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top